Last reviewed · How we verify
Ethinyl estradiol and norgestimate
At a glance
| Generic name | Ethinyl estradiol and norgestimate |
|---|---|
| Also known as | Ortho Cyclen |
| Sponsor | University of Vermont |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
- Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants (PHASE1)
- A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity
- To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada) (PHASE3)
- Premature Discontinuation of Contraceptive Implants (PHASE4)
- A Multicentre, Prospective, Open-label, Non-comparative Study (PHASE4)
- Inpatient Adolescent Contraception (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethinyl estradiol and norgestimate CI brief — competitive landscape report
- Ethinyl estradiol and norgestimate updates RSS · CI watch RSS
- University of Vermont portfolio CI